Please assess the completion status of the following clinical trial:

Trial Title: Rosiglitazone and Insulin Resistance in Renally Impaired Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CKD stage 4~* BMI ≤ 30~* Fasting glucose \< 7 mmol/l~Exclusion Criteria:~Exclusion of patients will take place in case of:~* A diagnosis of diabetes mellitus for which the patient uses insulin~* Significant co-morbidities which, according to the treating nephrologists, makes it unlikely that the patient will be able to complete the foreseen study period~* Significant cardiovascular co-morbidities which are likely to interfere with the objectives of the study (morbid obesity, family history of dyslipidemia, etc.); at the discretion of the treating nephrologists or the principal investigator~* Allergy for PPAR's~* Cardiac disease with marked limitation of functional capacity (New York Heart Association III or IV clinical status)~* Use of immunosuppressant agents~* History of renal transplant~* Hepatic insufficiency (defined as transaminase concentrations above \> 2.5 times the upper limit of normal for the laboratories)~* A history of alcohol abuse or excessive alcohol use defined as more than 21 consumptions per week~* For female patients: pregnancy, the intention to become pregnant within the study period, or lactating patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).